The Food and Drug Administration (FDA) has approved Dupixent (dupilumab; Sanofi and Regeneron) as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis ...

SanofiSNY and partner Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has granted priority review to a regulatory filing looking for label expansion of Dupixent for inadequately controlled ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced that the two phase III studies on Dupixent for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) were successful ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair ...

The FDA approved Dupixent for use with other medicines to treat patients with chronic rhinosinusitis with nasal polyps, the agency, Regeneron Pharmaceuticals and Sanofi all announced today. Sally ...

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Sept. 20, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that The Lancet has published detailed positive results ...

In both studies, at 24 weeks, patients treated with dupilumab plus corticosteroid nasal spray experienced a 51% and 57% improvement in nasal congestion/obstruction severity vs 15% and 19% improvement ...

First biologic approved in the European Union for adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) Dupixent now approved in the EU for three type 2 inflammatory diseases: severe ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...